Choosing where to export is a regulatory decision before it is a commercial one. The pharmaceutical export countries that look best on paper often have the longest registration queues and the highest dossier costs.
This guide is organised by region, covering the regulatory authority, the registration pathway, whether a Certificate of Pharmaceutical Product (CoPP) or GMP certificate is expected, local agent rules and labelling requirements.
Two things separate an easy market from a hard one. The first is assessment style: reliance markets accept the approval of a recognised stringent regulator and shorten their own review. The second is the CoPP, the WHO-format certificate issued where you manufacture. Reliance markets treat it as the anchor document; stringent regulators verify your site themselves.
You will not find market size figures here. Regulatory structure changes slowly and can be checked against the authority’s own guidance, which makes it more useful than trade data. Everything below reflects the position in 2026.
Which pharmaceutical export countries are easiest to enter? Entry difficulty depends on the regulator, not market size. The US, EU, Canada and Australia demand full dossiers, inspections and local entities. Africa, ASEAN and parts of Latin America accept CoPP-based or reliance registration, making them cheaper to enter first.
Table of Contents
- North America: US FDA and Health Canada
- Europe: EMA, National Routes and the UK MHRA
- Africa: Reliance Pathways and the African Medicines Agency
- Latin America: ANVISA, COFEPRIS and ANMAT
- GCC and the Wider Middle East
- Southeast Asia and the ASEAN Common Technical Dossier
- CIS and the Eurasian Economic Union
- Australia and New Zealand: TGA and Medsafe
- Comparing Pharmaceutical Export Countries Side by Side
- How to Choose Between Pharmaceutical Export Countries
- Expert Tips
- Common Mistakes
- Frequently Asked Questions
North America: US FDA and Health Canada
United States (FDA). The most demanding entry here. Generics go through an Abbreviated New Drug Application with bioequivalence data against the Reference Listed Drug, supported by a Drug Master File, in eCTD format. There is no CoPP route — the FDA verifies quality through establishment registration, drug listing and inspection.
A pre-approval inspection is common for a first filing, and a foreign manufacturer must appoint a US Agent as the FDA’s contact point. Labelling is English and review cycles are long.
Canada (Health Canada). Generics use the Abbreviated New Drug Submission in CTD format. Instead of a CoPP, Health Canada works through the Drug Establishment Licence held by the Canadian importer, with foreign site GMP evidence often accepted through recognised inspection agreements. A Canadian sponsor is required, labelling is bilingual English and French, and timelines are long.
Advice: enter both later, funded by easier markets. Bilingual artwork is the hidden cost.
Europe: EMA, National Routes and the UK MHRA
European Union. The centralised procedure through the European Medicines Agency gives one authorisation covering all member states and is compulsory for certain classes, including biotechnology products. For most generics the decentralised or mutual recognition procedure is the practical route, filing in several states at once or extending a national approval.
There is no CoPP route. You need EU-standard GMP compliance, evidenced by an EU GMP certificate or accepted under a mutual recognition agreement, and batches must be certified by a Qualified Person inside the EU.
The authorisation holder must be established in the EU or EEA, with a qualified person for pharmacovigilance. Labelling appears in each country’s official languages with braille, and timelines are long.
United Kingdom (MHRA). Great Britain issues its own authorisations, with separate arrangements for Northern Ireland. Recognition-based routes take account of approvals from trusted regulators, shortening review for products authorised elsewhere. A UK-based authorisation holder is required and importers need a UK Responsible Person.
Advice: budget for the EU infrastructure, not just the dossier. Our guide on importing pharmaceuticals into Europe has the detail.
Africa: Reliance Pathways and the African Medicines Agency
Africa is not one market. Maturity ranges from authorities running full independent assessment with their own inspections to agencies registering largely on a CoPP and GMP certificate. Established regulators include SAHPRA, NAFDAC, Kenya’s Pharmacy and Poisons Board, the Ghana FDA, the Egyptian Drug Authority and TMDA.
A CoPP in WHO format is the most requested document across the continent, usually with a GMP certificate and free sale evidence.
Reliance is the important trend. Regional collaborative procedures let one assessment support approvals in neighbouring countries, and some authorities shorten review for products prequalified by WHO — which also governs eligibility for donor-funded tenders. The African Medicines Agency points the same way, though its influence is still building.
A local agent is mandatory in most African countries, often holding the registration itself — a real risk if the relationship ends. Labelling is English, French, Portuguese or Arabic, and timelines are moderate.
Advice: Africa holds many of the most accessible pharmaceutical export countries. Insist on registrations in your own name where the law permits.
Latin America: ANVISA, COFEPRIS and ANMAT
Brazil (ANVISA). The most demanding regulator in the region and a full assessment authority. Dossiers follow a CTD-aligned national format in Portuguese, a genuine translation cost.
ANVISA issues its own GMP certification for foreign sites, typically after inspection, and that is a prerequisite for product approval. A Brazilian legal entity must hold the registration, and timelines are long.
Mexico (COFEPRIS). Faster treatment is available for products already approved by regulators COFEPRIS considers equivalent, and technical review can be supported through authorised third parties. A Mexican registration holder is required, documentation is in Spanish, and timelines are moderate.
Argentina (ANMAT). A tiered approach gives lighter treatment to products registered in countries classified as high-surveillance, so a CoPP carries real weight. A local representative is required and submissions are in Spanish. The complication here is commercial — check payment terms.
Advice: enter through Mexico or Argentina first, then use those approvals for Brazil.
GCC and the Wider Middle East
Saudi Arabia (SFDA). A stringent, well-documented process with published guidance and its own foreign inspection programme. Dossiers follow CTD, and GMP evidence plus a CoPP are normally required.
Company registration precedes product registration, a local authorised representative is mandatory, and pricing approval is separate. Arabic is required alongside English, and timelines are moderate to long.
United Arab Emirates (MOHAP). MOHAP registers both company and product and inspects overseas sites. CoPP and GMP certification are standard, a UAE-based agent is mandatory, and Arabic and English labelling applies. The UAE is often a regional launch point because of its logistics and re-export role.
GCC centralised registration. The Gulf states operate a central route through the Gulf Health Council, letting one submission support marketing across member states. National pricing and licensing still follow.
Advice: the central route suits several Gulf markets at once; for one country a direct filing is faster. Choose your agent carefully, because transfer rules are restrictive.
Southeast Asia and the ASEAN Common Technical Dossier
ASEAN developed its own harmonised structure, the ASEAN Common Technical Dossier or ACTD. It covers similar ground to the ICH CTD but arranges it differently, so a CTD file needs restructuring. Several member states now accept CTD too.
Philippines FDA. Importers need a License to Operate before any product application, and each product receives a Certificate of Product Registration. A CoPP and GMP certificate are required, a local licensed importer holds the registration, English labelling is accepted, and timelines are moderate.
Vietnam (DAV). Document-heavy and procedurally strict, with CoPP and GMP evidence central. Foreign manufacturers must be permitted to operate in the Vietnamese pharmaceutical sector, so a local partner is essential. Vietnamese labelling is required and timelines are long.
Indonesia (BPOM). BPOM inspects overseas sites itself and requires a local registration holder. Bahasa Indonesia labelling is required, halal obligations for medicines are being phased in, and timelines run long.
Advice: the Philippines is the most accessible ASEAN entry point.
CIS and the Eurasian Economic Union
The Eurasian Economic Union — Russia, Belarus, Kazakhstan, Armenia and Kyrgyzstan — has moved medicine registration onto common union rules. Applications run through a reference member state with the others recognising the outcome, or through a mutual recognition step for existing approvals.
Dossiers follow the EAEU’s own CTD-based structure with Russian-language documentation, and that translation effort is regularly underestimated.
GMP evidence must satisfy an EAEU member inspectorate, which usually means an inspection by a union authority rather than a foreign certificate. That inspection is often the critical path. A local representative is required and timelines are long.
Countries outside the union, including Ukraine, Uzbekistan and Azerbaijan, keep their own systems, and several accept CoPP-based registration.
Australia and New Zealand: TGA and Medsafe
Australia (TGA). Products are entered on the Australian Register of Therapeutic Goods, with generics using abridged pathways supported by bioequivalence data and CTD-format quality documentation.
There is no CoPP route. Manufacturers need GMP clearance from the TGA, which can be granted by verifying evidence from recognised inspectorates rather than a fresh inspection — a major time saver if you hold PIC/S-aligned certification. An Australian sponsor is mandatory and timelines are moderate to long.
New Zealand (Medsafe). Smaller and more pragmatic, applying abridged evaluation routes that recognise approvals from trusted overseas authorities. A New Zealand sponsor is required and labelling is English. The market is small, so it works best as an add-on to an Australian filing.
Comparing Pharmaceutical Export Countries Side by Side
| Region | Authority | Dossier | CoPP | Local Agent | Difficulty |
|---|---|---|---|---|---|
| United States | US FDA | eCTD | No | US Agent | Very high |
| Canada | Health Canada | CTD | No | Yes | High |
| European Union | EMA / national | eCTD | No | Yes, EU MAH | Very high |
| United Kingdom | MHRA | eCTD | No | Yes, UK MAH | High |
| Africa | NAFDAC, SAHPRA, PPB, EDA | CTD, varies | Yes | Yes | Low to moderate |
| Latin America | ANVISA, COFEPRIS, ANMAT | National CTD | Often | Yes | Moderate to high |
| GCC / Middle East | SFDA, MOHAP, GHC | CTD | Yes | Yes | Moderate to high |
| Southeast Asia | Philippines FDA, DAV, BPOM | ACTD | Yes | Yes | Moderate |
| CIS / EAEU | EAEU authorities | EAEU CTD | Varies | Yes | Moderate to high |
| Australia / NZ | TGA, Medsafe | CTD | No | Yes, sponsor | High / moderate |
How to Choose Between Pharmaceutical Export Countries
Registration cost against realistic volume. Add up dossier preparation, translation, agency fees, sample testing, legalisation, inspection and the local entity retainer, then ask how many units you must sell to recover it. The most stringent pharmaceutical export countries often fail this test for a newcomer.
Competition on your specific molecule. Attractiveness is molecule-specific, not country-specific. A crowded generic in a large market is a worse opportunity than a thinly supplied product in a mid-sized one. Where a regulator publishes its register of approved products, read it.
Tender business versus private market. Tenders reward scale, tight pricing and flawless documentation, and often demand WHO prequalification. Margins are thin and awards are lumpy. Private-market business pays better and depends on distributor capability. Chasing both means doing neither well.
Payment and currency risk. Registration effort is wasted if you cannot get paid. Check currency availability, whether import payments need central bank clearance, and how long public buyers take.
Expert Tips
- Build one master CTD dossier and maintain it. Country submissions then become extraction exercises rather than new projects.
- Track document expiry like batch expiry. An expired CoPP or GMP certificate mid-review can restart a queue.
- Get legalisation right first time. Notarisation, chamber attestation and embassy legalisation follow a set sequence; out of order means starting over.
- Register in your own name where the law allows. If the agent holds the registration, they hold your market access. Where local holding is mandatory, negotiate a transfer clause first.
- Start GMP certification in parallel with the dossier. In Brazil and the EAEU, site approval rather than product review is the critical path.
- Treat artwork as a project. Bilingual, Arabic and braille requirements each carry their own approval loop.
- Ask your agent for a comparable product’s real review history. An agent who cannot answer probably has not filed much.
Common Mistakes
- Ranking pharmaceutical export countries by population size. Price control and slow payment can make a large market worse than a small stable one.
- Assuming a CTD dossier drops into an ACTD submission. The structure differs, so the file gets returned before assessment.
- Letting the local agent own the registration. Ending the relationship can mean re-registering from scratch.
- Ignoring pricing approval as a separate step. Approval does not equal permission to sell, and launch stalls.
- Underestimating translation. Weak technical translation in Portuguese, Russian or Arabic triggers avoidable queries.
- Neglecting post-approval obligations. Missed variation, renewal and pharmacovigilance deadlines can suspend a registration.
Frequently Asked Questions
Which countries are the easiest pharmaceutical export markets to enter?
Markets that accept CoPP-based or reliance registration are generally easiest, including much of Africa, several ASEAN members such as the Philippines, and some Latin American and CIS countries. These authorities lean on the approval and GMP certification already granted where you manufacture, which cuts dossier work and cost.
Easiest does not mean easy — you still need a competent local agent, accurate documents and correct legalisation.
Do I need a CoPP for every pharmaceutical export country?
No. The CoPP matters most in markets that practise reliance, such as much of Africa, the Middle East, Southeast Asia and parts of Latin America. Stringent markets including the US, EU, UK, Canada and Australia do not use it as an entry document, because they assess your data and verify your site themselves.
Where required, it must be recent, in WHO format, and properly legalised.
What is the difference between CTD and ACTD dossiers?
The ICH Common Technical Document is the international five-module structure covering administrative, quality, non-clinical and clinical information. The ASEAN Common Technical Dossier arranges similar content into a different set of parts built for ASEAN member states.
The information overlaps heavily, but organisation and numbering differ, so a CTD cannot simply be relabelled as an ACTD. Several ASEAN countries now accept CTD too.
Is a local agent always required to export pharmaceuticals?
In most countries, yes, in some form — a local marketing authorisation holder, licensed importer, registered sponsor or designated representative. Even the US, which needs no commercial local partner for registration, requires a US Agent as the FDA’s contact point.
The role varies. An EU authorisation holder carries legal responsibility for the product, while an agent elsewhere may only handle submissions.
Which markets require WHO prequalification?
No country requires WHO prequalification for general registration. It matters commercially rather than regulatorily. Tenders funded by international health programmes and several large public procurement bodies restrict eligibility to prequalified products, or products cleared through an equivalent expert review.
If donor-funded tender business is part of your plan, particularly in Africa, prequalification becomes close to essential. For private-market sales it stays optional.
How long does drug registration take in emerging markets?
Realistically, longer than the published target. Reliance-based markets move fastest because the assessment is abridged. Countries that conduct full independent review, or require their own foreign site inspection, take considerably longer, and inspection scheduling is often the real bottleneck.
Query cycles add further time, because each deficiency letter and response round extends the clock. Ask your local agent what a comparable product from a similar manufacturer recently experienced.
Should I register in the US or EU first as a new exporter?
Usually neither. Both demand full dossiers, bioequivalence data, local legal entities and inspection-ready quality systems, and both consume a large budget before any revenue arrives. Most successful exporters build approval history and cash flow in accessible markets first, then use that track record to support a stringent filing.
The exception is a genuinely strong cost position on a molecule with limited competition.
What labelling languages do export markets require?
It depends entirely on the destination. English works across much of Africa, the Philippines and Australasia. The EU requires the official languages of each member state plus braille on the outer carton.
Canada requires English and French, Gulf markets expect Arabic alongside English, Brazil requires Portuguese, EAEU markets require Russian, and Vietnam and Indonesia require their national languages. Artwork approval is usually a separate step.
Final Thoughts
The best first market is rarely the biggest one. It is the one where your dossier, your documentation and your local partner are all ready, and where you can be paid on reasonable terms.
Get one or two right, keep the registrations in your name, and each later market gets cheaper to enter.
Speak With Our Pharmaceutical Experts
Choosing between pharmaceutical export countries is easier when documentation requirements are set against your own portfolio. If you are planning a first registration, contact our team to discuss your sourcing requirements.